CMZ-207: ‘KOURAGE’
🔹 Key Info:
- 💉 Drug: Auxora (zegocractin)
- Mechanism: a calcium release-activated calcium (CRAC) channel inhibitor with potent anti-inflammatory and pulmonary endothelial protective properties (https://pubmed.ncbi.nlm.nih.gov/40489964/)
- 👥 Eligibility: adult patients with AKI who are hypoxemic: P/F<300 (can be imputed from SpO2/FiO2) on HFNC, NIV, or vent
- Multicenter, phase 2, randomized, double blind, placebo-controlled
- Randomized 1:1 to receive five daily IV doses vs placebo
- 🎯Objectives: safety, efficacy; days alive, ventilator-free, kidney replacement therapy-free
- 👩🔬PIs/SIs: Drs. Pickens, Wunderink, Jose & Russell
- Link: https://clinicaltrials.gov/study/NCT06374797
📟 Have a patient or questions? Page the MICU Research Team at 59285